- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06329492
Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis (A2MRP)
April 9, 2024 updated by: Brennan J. Boettcher, Mayo Clinic
Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP), Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis: A Pilot Study
The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
The overall objective of this study is to test and quantify A2MRP and prepare for a larger randomized clinical trial assessing the efficacy of A2MRP injections in primary and post traumatic knee osteoarthritis (OA) with respect to clinical outcomes and disease progression.
The study will also assess safety of A2MRP intraarticular injection in patients with symptomatic knee OA.
Patients with symptomatic mild to moderate knee OA (KL 2-3) will be candidates for this study.
Baseline data will include physical examination of the knee, clinical assessment of knee pain and function using validated patient reported outcome measures (PROMs), and radiologic exam of the knee will be obtained.
All injections will be performed using ultrasound guidance and all patients will followed-up at week 1 week post-injection for acute adverse events (AEs).
Each subject will be clinically followed-up for study endpoints using a predetermined protocol.
PROs will be collected during the study period pre-procedure, and at 1, 2, and 6 weeks, 3-, 6-, 9- and 12-months post-procedure (Specific PRO's and timepoints noted in sections 6.2-6.7).
Subjects will also be asked questions regarding satisfaction with the treatment and whether they would recommend the treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or females,18-65 years of age
- Chronic (> 3 months), unilaterally symptomatic, primary knee OA.
- Painful knee OA in one or more knee compartments grade 2-3 radiologic severity based upon the Kellgren-Lawrence grading scale, without evidence of advanced (bone on bone, as determined by study investigators) OA in the patellofemoral compartment or on Posterior Anterior (PA) flexion views
- Cognitive ability to give informed consent
- Speak fluent English
- Worst knee pain greater than 4 on a 0-10 pain scale (0 = no pain, 10 = worst pain imaginable)
- Previous 6 week or longer trial of one of the following conservative treatments: activity modification, weight loss, physical therapy, anti-inflammatory medications/acetaminophen or injection therapy (e.g., cortisone)
- Fully understanding of the requirements of the study and willingness to comply with the treatment plan, including blood draw, laboratory tests, diagnostic imaging, and follow-up visits and assessments
- Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related procedure.
Exclusion Criteria:
- Pregnant or nursing, or planning on becoming pregnant during the study period
- Congenital or acquired malformation of the target knee resulting in significant deformity or leading to problems with the study treatment or analysis of the results
- Significant valgus or varus malalignment as determined by investigator
Injections of any kind into the target knee:
- Corticosteroid injections within 3 months prior to study enrollment
- Hyaluronic acid injections within 6 months prior to study enrollment
- PRP injection within the year prior to study enrollment
- History of BMAC, Micro-Fragmented Adipose Tissue (MFAT), or perinatal product injection at any point
- History of intra-articular infection in the target knee
- History of superficial infection in the target knee within 6 months of study enrollment, or evidence of current superficial infection affecting the target knee
- Body mass index (BMI) > 35 kg/m2
- Inability to stop non-steroidal anti-inflammatory medications for 1 week before through 2 weeks after the procedure date
- On chronic, immunosuppressive transplant therapy or having a chronic, immunosuppressive state, including use of systemic steroids/corticosteroids
- Current tobacco product use, including nicotine patch or other nicotine products
- Clinically significant rheumatological or inflammatory disease or chondrocalcinosis/ calcium pyrophosphate disease (CPPD), hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, systemic sclerosis, system lupus erythematosus, and Ehlers-Danlos Syndrome, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis
- Surgery in the target knee within the last 12 months, or planned surgery in the target knee in next 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)
Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is produced by filtering Platelet Poor Plasma (PPP), a Platelet Rich Plasma byproduct, through a hemoconcentrator filter.
(PPP) is frequently used in clinical practice to increase volume of PRP or Bone Marror Aspirate Concentrate (BMAC) injectate, and it is occasionally injected in isolation for some indication
|
Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait.
This will take approximately 30 minutes.
When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint.
You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space.
If there is excessive fluid in your knee, this may be drained before the injection is performed.
The needle will be removed, and a band aid will be placed over the injection site.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 1 year
|
The number of Adverse Events reported
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analog Scale (VAS) for Pain
Time Frame: 1 year
|
The VAS is a 11-item questionnaire assessing pain.
Using a scale of 0 = no pain to 10 = worst pain.
Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain.
|
1 year
|
Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Pain interference
Time Frame: 1 year
|
The PROMIS-CAT: Pain interference is a 40-item questionnaire assessing pain.
Using a scale of 1 = not at all to 5 = very much.
Total scores range from 40-200, lower scores indicating lower pain and higher scores indicating greater pain.
|
1 year
|
Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Physical function
Time Frame: 1 year
|
The PROMIS-CAT: Physical function is a 165-item questionnaire assessing physical function.
Using a scale of 1 = unable to do to 5 = without any difficulty.
Total scores range from 165-825, lower scores indicating less physical function and higher scores indicating greater physical function.
|
1 year
|
Knee Injury and Osteoarthritis Outcome Score (KOOS):
Time Frame: 1 year
|
KOOS is a commonly used questionnaire which focuses on how patients are affected by knee problems in five areas: knee pain, stiffness, daily activity, sport and recreation, and quality of life.
Results are scored 0-100.
0 = extreme knee problems, 100 = no knee problems
|
1 year
|
Procedure Recommendation
Time Frame: 1 year
|
The number of subjects to answer "yes" to the question "Would you recommend this procedure to someone with a similar condition as your own?"
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Brennan Boettcher, D.O, Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2024
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 27, 2024
First Submitted That Met QC Criteria
March 18, 2024
First Posted (Actual)
March 26, 2024
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-007937
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Mayo ClinicCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Sword Health, SAHospital da PreladaCompletedEfficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint ReplacementKnee Osteoarthritis | Hip OsteoarthritisPortugal
-
The Hawkins FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Massachusetts General HospitalNewton-Wellesley HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)
-
Rajavithi HospitalRecruitingAutologous Platelet-rich Plasma Supplement | Sperm Cryopreservation | Post-cryopreserved Sperm Quality | Semen AnalysisThailand
-
Assiut UniversityUnknownAutologous Platelet Rich Plasma Effect on Bone Healing
-
Mayo ClinicCompleted
-
Center for Vulvovaginal DisordersCompletedLichen Sclerosus
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Santiste Medical Inc.Recruiting
-
University of Colorado, DenverCompletedPlatelet-Rich PlasmaUnited States
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
Matthew GettmanCompleted
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingInfertility, Female | Ovarian Failure | Ovarian Insufficiency | Poor Response to Ovulation Induction | Reproductive Sterility | Ovary; AnomalyGreece